SCHEMBL3490784

SCHEMBL3490784

Nc1cc(Cl)cc(Cl)c1S(=O)(=O)NCc1ccccc1Br

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
NR3C1 P04150 6/20 0.45
NR3C2 P08235 6/20 0.45
PGR P06401 3/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP3A4 P08684 3/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
GUSB P08236 1/20 0.39
ACLY P53396 1/20 0.38
PRNP P04156 1/20 0.38
MAPK1 P28482 1/20 0.38
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3491958 0.88 KMT2A (0.54) HPGDNR3C1NR3C2PGRMEN1
SCHEMBL3490963 0.85 KMT2A (0.50) HPGDL3MBTL1NR3C1NR3C2PGR
SCHEMBL3488988 0.85 MEN1 (0.50) HPGDNR3C1NR3C2PGRMEN1
SCHEMBL3490906 0.82 CA2 (0.53) NR3C1NR3C2PGRMEN1KMT2A
SCHEMBL9272679 0.81 NR3C1 (0.48) NR3C1NR3C2PGRMEN1KMT2A
SCHEMBL3489252 0.81 MEN1 (0.54) NR3C1NR3C2PGRMEN1KMT2A
SCHEMBL3491178 0.81 LMNA (0.52) L3MBTL1NR3C1NR3C2PGRMEN1
SCHEMBL3488511 0.81 CA12 (0.52) L3MBTL1NR3C1NR3C2PGRMEN1
SCHEMBL3489635 0.79 CYP19A1 (0.43) NR3C1NR3C2PGRMEN1KMT2A
SCHEMBL3489981 0.79 CYP19A1 (0.47) NR3C1NR3C2PGRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D HPGD 796/4885L3MBTL1 3136/4885NR3C1 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.